TICKERNERD
Menu
SCTXHealthcare · Biotechnology

SCTX Stock Forecast: Scribe Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 29 Oct 2026
$17
−0.57% on the day

The 4 Wall Street analysts covering Scribe Therapeutics, Inc. hold a median 12-month price target of $59 — +238.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 2 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$302.1M
Ticker Nerd rank
2/ 100
Median analyst target
$59
Analysts covering
4
Revenue$1.9M
Operating income−$9.4M
Net income−$6.5M
Free cash flow−$5.3M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.9%
1M
−24.3%
From high
−53.2%
From low
+13.2%
$15
$37
Range since 24 July 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

SCTX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Scribe Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 28 Oct 2026
2/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
59
Revisions
44
Value
8
Accruals
8
Growth
8
Momentum
7
Volatility
4
Quality
3
Issuance
1

Size (59): Smaller than most of the companies we track.

Issuance (1): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

SCTX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SCTX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 24 July 2026Adjusted close, US dollars
$10$20$30$40$50$60Aug 26Sep 26Oct 26SCTXHigh $60Median $59Low $50

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4 Buy0 Hold0 Sell
Low $50Median $59High $60

The green dot is the last close — the median target sits +238.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$60
31 Aug 2026HC Wainwright & Co.InitiatesBuy$60
18 Aug 2026GuggenheimInitiatesBuy$50
18 Aug 2026GuggenheimInitiatesBuy—
18 Aug 2026Leerink PartnersInitiatesOutperform$37
18 Aug 2026Leerink PartnersInitiatesOutperform—
18 Aug 2026Wells FargoInitiatesOverweight—
18 Aug 2026Wells FargoInitiatesOverweight$60

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

SCTX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

SCTX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

SCTX vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160Aug 26Sep 26Oct 26SCTXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SCTX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Scribe Therapeutics, Inc. (SCTX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
9.1×

Cheaper than 15% of US stocks

Price / book
−1.6×

Cheaper than 95% of US stocks

EV / EBITDA
−15.2×

Cheaper than 88% of US stocks

Growth & margins
Revenue growth (YoY)
−60.8%

Higher than 4% of US stocks

Earnings growth (YoY)
—
Gross margin
—
Operating margin
−489.8%

Higher than 8% of US stocks

Net margin
−97.0%

Higher than 6% of US stocks

Returns & dividend
Return on equity
15.2%

Higher than 74% of US stocks

Return on assets
−27.9%

Higher than 15% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Scribe Therapeutics, Inc. (SCTX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Scribe Therapeutics, Inc. has a market value of $302.1M and an enterprise value of $422.8M.

  • Revenue in the twelve months to 30 June 2026: $26.2M. The latest quarter shrank 60.8% year on year.

  • Net income over the same four quarters: −$37.2M, a −141.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$34.1M.

  • Shares outstanding: 17.6M.

  • forward P/E: −4.4× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Scribe Therapeutics, Inc. employs 82 people — $319K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 29 Oct 2026

Data provided by Twelve Data

Peers

SCTX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SCTXScribe Therapeutics, Inc.$302.1M2
PRLDPrelude Therapeutics, Inc.$329.7M91
XFORX4 Pharmaceuticals, Inc.$332.1M61
ALECAlector, Inc.$333.6M55
TTRXTurn Therapeutics, Inc.$327.4M22
ENTAEnanta Pharmaceuticals, Inc.$336.4M91
AVIRAtea Pharmaceuticals, Inc.$342.5M74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Scribe Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SCTX news & analysis

Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst

Seeking Alpha · 15 Oct 2026positive

Seeking Alpha initiated coverage of Scribe Therapeutics with a buy rating, highlighting STX-1150, an in-vivo gene therapy candidate targeting PCSK9 for cholesterol lowering. The excerpt cites preclinical primate data showing 52–68% LDL-C reduction for at least two years, funding into 2029, and partnerships with Sanofi and Eli Lilly.

Why it matters — SCTX watchers may note the reported candidate data, funding runway, and partnerships as factors highlighted in the coverage.

Scribe Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

GlobeNewsWire · 2 Sept 2026positive

Scribe Therapeutics reported second quarter 2026 financial results and corporate updates, including initiating a Phase 1 trial of STX-1150 for LDL-C lowering, receiving over $25 million from CIRM to advance its STX-1200 and STX-1400 programs, and completing an upsized IPO and concurrent private placement to Sanofi that generated approximately $155.5 million in gross proceeds. The company ended June 30, 2026, with $43.0 million in cash, plus around $140.6 million in net proceeds from the July 2026 IPO, providing funding into the first half of 2029.

Why it matters — The results show progress across multiple pipeline programs and significant new funding via the IPO and Sanofi partnership that extends the company's cash runway into the first half of 2029.

Scribe Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Scribe Therapeutics announced that its management will participate in upcoming investor conferences, including the Wells Fargo Healthcare Conference in Boston, Massachusetts, in September. The company is a clinical-stage biotechnology firm developing in vivo CRISPR technologies.

Why it matters — SCTX watchers would care because the company's participation at investor conferences provides an opportunity for management to present its pipeline and engage with investors.

FAQ

Frequently asked questions about SCTX stock

What is the SCTX stock price forecast for 2026-2027?

The 4 Wall Street analysts covering Scribe Therapeutics, Inc. have a median 12-month price target of $59, with estimates ranging from $50 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SCTX stock a buy right now?

Of the 4 analysts covering Scribe Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Scribe Therapeutics, Inc. 2 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SCTX?

As at 28 Oct 2026, Scribe Therapeutics, Inc. ranks 2 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (59 of 100).

Will SCTX stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts implies +238.3% from the last close, and Ticker Nerd's factor model ranks Scribe Therapeutics, Inc. 2 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SCTX stock forecast for 2030?

No analyst covering Scribe Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SCTX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $50 to $60 over the next 12 months.

What does Scribe Therapeutics, Inc. do?

Scribe Therapeutics Inc. is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines.

What is the latest news on SCTX?

The most recent item we track (Seeking Alpha, 15 Oct 2026): "Scribe Therapeutics: Underrated In-Vivo Gene Therapy Developer With Near-Term Catalyst". Seeking Alpha initiated coverage of Scribe Therapeutics with a buy rating, highlighting STX-1150, an in-vivo gene therapy candidate targeting PCSK9 for cholesterol lowering. The excerpt cites preclinical primate data showing 52–68% LDL-C reduction for at least two years, funding into 2029, and partnerships with Sanofi and Eli Lilly.

Company

About Scribe Therapeutics, Inc.

Scribe Therapeutics Inc. is a clinical-stage biotechnology company focused on developing in vivo CRISPR-based genetic medicines. Its platform uses custom-engineered enzymes and delivery technologies to create precise therapies designed to address the root causes of disease. The company’s current work centers on cardiometabolic conditions, including cardiovascular and metabolic diseases, with programs aimed at key drivers of atherosclerotic cardiovascular disease. Scribe Therapeutics also advances epigenetic silencing approaches intended to deliver durable therapeutic effects without permanently altering DNA. Based in Alameda, California, Scribe Therapeutics operates at the intersection of gene editing, molecular engineering, and drug development, serving the growing field of genetic medicine with technologies designed for broad clinical use in common diseases.

CEO Dr. Benjamin L. Oakes Ph.D. · 82 employees · United States · https://www.scribetx.com